Project Grant R41HL186958
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $315K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78750, USA
Similar Awards
- The Defense Health Agency awarded $1.7 million to Versiti Blood Health, Inc. on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a countermeasure for microthrombosis and tissue injury in freezing cold injury that prevents pathologic fibrinogen elevation. The award runs through June 30, 2029, with performance at Versiti's Milwaukee, Wisconsin location. The project grant is one of six Defense Health Agency awards to Versiti, which operates the...
- The National Heart Lung and Blood Institute awarded North Carolina State University $698,083 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop hemostatic B-knob triggered microgels that leverage age-dependent clotting mechanisms for treating pediatric trauma-associated hemorrhage. The project addresses life-threatening bleeding in pediatric trauma patients, where hemorrhagic shock is a common cause of death. Current treatment relies on...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,932 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer and scale production of red blood cells derived from human induced pluripotent stem cells (iPSCs) for two high-impact applications: alloantibody detection and neonatal transfusion therapy. The project addresses urgent clinical needs in two vulnerable patient populations. Sickle cell disease...
- The National Heart, Lung, and Blood Institute awarded Emprime Therapeutics Inc. $314,363 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the STITCHR dual adeno-associated virus vector technology for full-length Factor VIII gene delivery in hemophilia A. The recipient will engineer robust AAV constructs for FVIII gene delivery, evaluate tissue-specific promoters to optimize FVIII expression and durability, and assess therapeutic...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate red blood cell transfusion characteristics in intracranial hemorrhage patients. The research examines how variations in red blood cell component and donor characteristics affect transfusion efficacy and patient outcomes in intracranial hemorrhage, a life-threatening condition...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Bloodworks $724,351 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, to investigate the mechanisms by which extracellular mitochondria released from traumatic brain injury sites cause endothelial cell injury and contribute to hemostatic dysfunction and coagulopathy. The research addresses a gap in understanding subcellular changes in endothelial cell injury during traumatic...
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...
- The National Heart, Lung, and Blood Institute awarded Stasys Medical Corp $325,648 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish ISO 13485–compliant manufacturing for test cartridges supporting the ATLAS platelet function diagnostic platform. The project delivers a scalable production line for single-use test cards containing microfluidic chips with shear-activating force sensors designed to detect platelet micro-clots. Work includes...
- The National Heart, Lung, and Blood Institute awarded Daris LLC $686,134 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an automated ex situ organ perfusion system for heart preservation and transplantation. Daris LLC, a startup company, will enhance the mechanical, electrical, and software components of its MFLOW system and test the modifications in vitro to ensure precise control and monitoring of perfusion parameters. The company...
- The National Heart, Lung, and Blood Institute awarded Lawrence Technological University $444,589 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop multiscale computational modeling for assessing shear-induced bleeding risk in blood-contacting medical devices. The research addresses device-induced complications in blood-contacting medical devices used to manage and treat heart conditions. The project develops physics-based computational models to...